Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: A randomized, single-center phase II trial

Journal of Chemotherapy

Volumn 11, Issue 4, 1999, Pages 278-286

  Engervall, P ^a   Kalin, M ^a   Dornbusch, K ^a   Bjorkholm M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cefepime; Leukemia; Neutropenia; Septicemia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RASH; SEPTICEMIA; TREATMENT OUTCOME;

EID: 0032802428     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.4.278     Document Type: Article

References (24)

1. Pizzo PA, Hathom JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic-therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
2. Sanders JW, Powe NR, Moor RD. Ceftazidime monotherapy for empiric treatment of neutropenic patients: a metaanalysis. J Infect Dis 1991; 164: 907-16.
3. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P. Ceftazidime compared with piperacillin and tobramycin for empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834-44.
4. Leyland MJ, Bayston KF, Cohen J et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with hematological malignancies. J Antimicrob Chemother 1992; 30: 843-54.
5. Rolston KVI, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-91.
6. Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-76.
7. The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherpay of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185-200.
8. Engervall P, Björkholm M. Infections in neutropenic patients. Part I: Etiology. Med Oncol 1996; 12: 251-6.
9. Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 47: 471-505.
10. Eggimann P, Glauser MP, Aoun M, Neunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993; 32 (Suppl. B): 151-63.
11. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100 (suppl. 6A): 83S-9S.
12. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704-8.
13. Engervall P, Stiernstedt G, Günther G, Björkholm M. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders. J Chemother 1992; 4: 99-106.
14. Engervall P, Günther G, Ljungman P, et al. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Scand J Infect Dis 1996; 28: 297-303.
15. Swedish Reference Group for Antibiotics. Referens och metodbok. Resistensbestämning av bakterier mot antibiotika. In Swedish. 1990-1996.
16. Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29: 533-8.
17. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397-401.
18. Kinsey SE, Machin SJ, Goldstone AH. Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. J Hosp Infect 1990; 15: 49-53.
19. Samuelson J, Lonnqvist B, Palmblad J, et al. Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Scand J Infect Dis 1992; 24: 89-96.
20. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-8.
21. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not essential component of the initial empirical treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36: 1062-7.
22. Compeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram-positive bacteremia and the impact of empirical administration of Vancomycin. Eur J Cancer 1996; 32A: 1332-9.
23. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105-13.
24. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agent Chemother 1996; 40: 1108-15.